. To show the patients with JIA receiving a monotherapy (with ETN, ADA or MTX) or a combination therapy and the number of uveitis diagnoses. Background: Delayed puberty is common in children with chronic illnesses such as Juvenile Idiopathic Arthritis (JIA),especially in cases with an earlier age of onset.Its etiology is multifactorial and includes low weight,complications arising from the disease itself and the adverse effects of treatment. Objectives: To compare uterine and ovarian size as well as artery pulsatility between girls with juvenile idiopathic arthritis (JIA) and healthy participants using abdominal pelvic ultrasound,and identify these findings and pubertal staging,sex hormones and disease characteristics in girls with JIA. Methods: This study involved 44 girls with JIA and 59 healthy controls aged between six and 18 incomplete years.Pelvic ultrasound was used to determine uterine volume and length,the corpus/cervix ratio,ovarian volume and length,and the pulsatility index (PI) of uterine arteries.Hormone levels were also measured in girls with JIA. Results: All US parameters were associated with Tanner stages in the control group (p<0.001).Uterine and ovarian measures were smaller in girls with JIA
Objectives: To analyze Th1 and Th17 cell subsets in patients with ERA and to compare with age-matched healthy controls. To assess the association between disease activity and disease clinical pattern with Th1and Th17 cells subsets Methods: Patients with ERA (according to ILAR criteria) were included in a cross sectional study. Disease activity measures were collected in random visits: active joint count (AJ), pain score (0-10), presence of active enthesitis (AE), sacroiliac pain (SIP), lumbar pain (LP),lumbar limitation (LL) by Schöber's test, wellbeing according to the patient using a visual analogue scale (VASp, 0-10), disease activity according to the physician (VASphy, 0-10), JADAS-10, JSpADA, and ESR/CRP were evaluated. Patients were classified based on the disease pattern (peripheral and non-peripheral) depending on the presence or absence of AJ and/or AE. Functional capacity was also assessed by CHAQ. Presence of radiologic sacroiliitis (MRI/X-rays) and treatment with TNF inhibitors (TNFi) were recorded. Th-17 and Th-1 cells were quantified by flow cytometry in PBMCs stimulated with PMA/IO. Age-matched healthy children without disease or medication were recruited as normal control. Comparison between groups (Mann-Whitney Utest) and correlation tests as appropiate Results: Twenty-nine patients (90% M) fulfilled inclusion criteria. HLA-B27 was positive in 13 (45%). Median age at observation was 12 years and median disease duration was 2.1 years. Activity and functional measures were (medians): AJ 1, pain 0.25, VASp 0.5, VASphy 1, JADAS-10 7, JSpADA 1.75, ESR 15 mm/h, and CHAQ ≥0,5=8 patients (27%). AE was present in 1 (3%), SIP in 7 (24%), LP in 6 (21%), and LL in 12 (41%) children. Nineteen (65%) patients showed JADAS >1 and 21 (76%) JSpADA>0. Radiologic sacroilitis was recorded in 21 (72%) children. Fourteen (48%) patients were treated with TNFi. Th1cell percentage in ERA was 8.5±3.4% (range, 4-17.4) while healthy controls was 5.8±3.8% (range, 1.2-14.2), p=0.023. Th17cell% in ERA was 0.90±0.44 (range, 0.39-2.34%) while controls was 0,55±0.38 (range, 0,17-1,61%); p=0.004. There was no difference between T-cells% and active/inactive disease. Eighteen (62%) children showed peripheral pattern, while 11 (38%) exhibited non-peripheral. Peripheral and non-peripheral groups showed Th17%cells 0.90 (0.39-1.74) vs 1.14 (0.64-2.44) respectively (p=0.018).Significant correlations were Th1 with AJ (r=0.45 p=0.004) and Th17with LP (r=0.83 p=0,0001), LL (r=0.47 p=0.03). Conclusions: Th1 and Th17 cells subsets were significantly higher in ERA compared with healthy controls. However, T-cells showed no significant difference between patients with active versus inactive disease. Interestingly, non-peripheral pattern showed higher Th17% cells respect to patients with peripheral disease.Our results suggest that Th17 evaluation could help identify different phenotypes that benefit from Th-17 blocking strategies. Background: MRP8/14 (also known as calprotectin) has been widely studied as
